The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to Germany-based brain-computer interface (BCI) company CorTec GmbH for its Brain Interchange system, an investigational implant designed to restore movement in patients with stroke-related neurological impairments. The designation is intended to accelerate development and regulatory review for technologies that address serious conditions with unmet clinical need, underscoring the potential of CorTec’s approach in stroke rehabilitation.
Brain Interchange is a fully implantable, bidirectional BCI platform that uses direct cortical electrical stimulation to create a communication loop between the brain and external rehabilitation systems. The device records neural activity and delivers adaptive stimulation in real time, forming a closed-loop system that can respond dynamically to a patient’s brain signals. This approach aims to help retrain neural pathways and restore motor function after stroke, rather than simply compensating for lost abilities.
The designation places CorTec among a small group of global BCI innovators—including Neuralink, Synchron, and Blackrock Neurotech—that have received similar FDA recognition. CorTec’s platform is notable for its focus on therapeutic intervention and its fully implantable design, which distinguishes it from some competing systems that are either partially external or focused on assistive communication rather than recovery of function.
The milestone builds on recent clinical progress. In 2024, CorTec received FDA Investigational Device Exemption and institutional approvals to begin human trials in the United States. The company has since completed initial implantations at Harborview Medical Center in Seattle, with procedures conducted under an FDA-approved study led by researchers from UCLA and the University of Washington. Early results are contributing to the growing body of evidence supporting closed-loop neurostimulation as a potential pathway for functional recovery after neurological injury.
As the BCI field continues to expand, the FDA’s designation highlights increasing momentum behind technologies that aim not only to interface with the brain, but to restore lost neurological function. CorTec’s Brain Interchange system represents part of a broader shift toward therapeutic, implantable neurotechnology that could reshape rehabilitation for stroke and other neurological conditions.
Click here to read the original news story.